clarithromycin + amoxicillin + tripotassium bismuth dicitrate + lansoprazole

This drug is a **fixed-dose combination of four agents**: clarithromycin (a macrolide antibiotic), amoxicillin (a penicillin antibiotic), tripotassium bismuth dicitrate (a bismuth salt), and lansoprazole (a proton pump inhibitor). It is used as **bismuth quadruple therapy** for the eradication of *Helicobacter pylori* infection, a major cause of peptic ulcer disease and gastritis. Lansoprazole suppresses gastric acid secretion, creating an environment unfavorable for *H. pylori* and increasing the efficacy of antibiotics. Amoxicillin and clarithromycin act directly to inhibit *H. pylori* growth by inhibiting cell wall synthesis and protein synthesis, respectively. Tripotassium bismuth dicitrate provides a local antimicrobial effect and protects the gastric mucosa. Bismuth-based quadruple therapy is particularly utilized in regions with high rates of antibiotic resistance or as a second-line therapy following failure of standard triple regimens[3].

Other names

bismuth quadruple therapy with clarithromycin